-
Decoy Therapeutics Stockholders Re-elect Directors, Approve Executive Pay and Auditor at 2026 Annual Meeting
Quorum of 42.4% (225,548 of 531,968 shares) present at July 14, 2026 Annual Meeting.
-
Decoy Therapeutics raises $3.5M upfront in PIPE, up to $21M with milestone warrants
Gross proceeds of $3.5M from sale of 592,217 shares (or pre-funded warrants) at $5.91/share.
-
Decoy Therapeutics sets July 14, 2026 annual meeting; proposal deadline May 29
Annual meeting of stockholders scheduled for July 14, 2026; record date May 22, 2026.
-
Decoy Therapeutics regains Nasdaq minimum bid price compliance after reverse split
Nasdaq confirmed compliance on March 31, 2026; Common Stock bid price closed at $7.47 on March 20, 2026.
-
Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance
Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.
-
Decoy Therapeutics shareholders approve 2026 equity plan and reverse stock split
Approved 2026 Equity Incentive Plan: 351,837 for, 68,978 against, 55,703 abstentions.
-
Salarius Pharmaceuticals renames to Decoy Therapeutics; ticker changes to DCOY effective Jan 8, 2026
Name change to Decoy Therapeutics Inc. and ticker symbol change from SLRX to DCOY effective January 8, 2026.
-
Salarius shareholders re-elect directors, approve executive compensation, ratify EY as auditor
Votes for Hanish: 143,525; against: 11,932; abstain: 5,761; broker non-votes: 256,225.
-
Salarius receives Nasdaq delisting notice for bid price non-compliance; appeal planned
Nasdaq notified Salarius on Dec 31, 2025 that bid price closed below $1.00 for 30 consecutive days.
-
Salarius annual meeting adjourned due to lack of quorum; reconvened Dec 31
Only ~30% of shares voted; 34% quorum required; meeting adjourned without business.
-
Salarius Pharma appoints CEO, CSO, CBO with $225k salary and 35% bonus
Frederick E. Pierce appointed CEO, Dr. Barbara Hibner as CSO, Peter Marschel as CBO effective upon merger closing.
-
Salarius Pharmaceuticals corrects false delisting reports; remains listed on Nasdaq
Company statement that stock continues trading on Nasdaq Capital Market under ticker SLRX despite inaccurate Yahoo Finance and CapIQ delisting reports.
-
Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering
Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.
-
Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger
Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.
-
Salarius regains Nasdaq equity compliance; fully compliant ahead of Decoy merger
Received Nasdaq letter on Oct 10, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
-
Salarius raises $6.2M; believes Nasdaq equity compliance regained ahead of Oct 20 deadline
Raised $2.4M from ATM sales (434,882 shares) and $3.8M from C/M Capital Master Fund purchase agreement.
-
Salarius amends merger deal with Decoy; sets preferred conversion floor at $3.75
Fifth Amendment to Merger Agreement sets initial conversion price at $10.50/share for Series A & B Preferred.
-
Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing
Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.
-
Salarius Pharmaceuticals receives Nasdaq extension to regain equity compliance by Oct 20, 2025
Nasdaq Hearings Panel granted Salarius until October 20, 2025 to comply with the Equity Standard (Rule 5550(b)(1)).
-
Salarius amends merger with Decoy; legacy holders diluted to 7.6%
Effective ownership post-merger: Salarius legacy holders 7.6%, Decoy holders 92.4% (pre-Qualified Financing).
-
Salarius Pharmaceuticals files $2.6M ATM equity offering via Ladenburg Thalmann
Offering of up to $2.6M of common stock at-the-market under existing S-3 shelf registration.
-
Salarius-Decoy merger update: legacy holders ~7.6% stake, $6M minimum financing required
Step one: Decoy stockholders receive ~92.4% of Salarius; legacy holders ~7.6% based on exchange ratio.
-
Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO
David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.
-
Salarius Pharmaceuticals effects 1-for-15 reverse stock split to regain Nasdaq compliance
Reverse split effective 5:00 p.m. ET on August 15, 2025; trading on split-adjusted basis from August 18, 2025.
-
Salarius Pharma expects Q2 net loss ~$900K, cash $800K; raises $3.8M via equity line
Preliminary Q2 2025 net loss ~$900,000; cash at June 30 was $800,000.
-
Salarius amends Decoy merger: removes $2M threshold, changes conversion price adjustment
Fourth Amendment dated July 29, 2025 removes $2M threshold for 'subsequent financing' triggering conversion adjustment.
-
Nasdaq Hearings Panel grants SLRX additional extension to regain listing compliance by August 2025
Equity Standard compliance deadline extended to mid-August 2025 from late July.
-
Salarius amends merger agreement to allow Decoy noteholders to exchange debt for Series B Preferred
Third Amendment dated July 18, 2025 allows holders of Decoy promissory notes to exchange debt for newly created Series B Non-Voting Convertible Preferred Stock.
-
Salarius gets additional Nasdaq extension to late July 2025 for equity standard compliance
Nasdaq Hearings Panel extended deadline to regain Equity Standard compliance to late July 2025.
-
Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance
Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.
-
Salarius gets Nasdaq extension to regain listing compliance; milestones set for July/August 2025
Nasdaq Hearings Panel granted extension to comply with Minimum Bid Price and Equity Standards.
-
Salarius cuts merger valuation from $4.6M to $2.31M; legacy holders drop to 7.6%
Parent Valuation reduced to $2.31M, down from $4.6M in original Jan 2025 merger agreement.
-
Salarius Pharma receives Nasdaq delisting notice for bid price non-compliance; merger with Decoy planned
Nasdaq notice on April 23, 2025 for failing minimum $1.00 bid price for 30 consecutive business days.
-
Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall
Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.
-
Salarius Pharmaceuticals files prospectus supplement for ATM offering of up to $417,000
Filed prospectus supplement on March 10, 2025 for at-the-market offering of up to $417,000 of common stock.
-
Salarius Pharma reports $2.4M preliminary cash; sells 141K shares for $493.5K
Cash and cash equivalents estimated at $2.4M as of Dec 31, 2024 (preliminary, unaudited).
-
Salarius to merge with Decoy; Decoy valued at $28M, legacy holders ~14.1% ownership
Merger structured as stock-for-stock with Decoy valued at $28M and Salarius at $4.6M, based on cash at close.
-
Salarius stockholders re-elect directors, approve say-on-pay, ratify auditor at annual meeting
Two Class III directors re-elected: Tess Burleson (141,974 for) and Paul Lammers (145,485 for).
-
Salarius enters $10M equity purchase agreement with C/M Capital Fund
Up to $10M of common stock may be sold over 36 months at 95% of VWAP or closing price.
-
Salarius sets 2024 annual meeting for Dec 20; proposal deadline Oct 7
Annual meeting set for December 20, 2024; record date October 25, 2024.
-
Salarius raises ~$1.5M to meet Nasdaq minimum equity requirement after being below $2.5M threshold
As of June 30, 2024, stockholders' equity was $2,375,353, below Nasdaq's $2.5M minimum.
-
Salarius files ATM offering prospectus supplement for up to $335,921 in common stock
Filed Prospectus Supplement on July 25, 2024 for at-the-market offering of up to $335,921 of common stock.
-
Salarius Pharmaceuticals files prospectus supplement for up to $335,921 ATM stock offering
Offering of up to $335,921 in common stock under existing ATM agreement with Ladenburg Thalmann & Co. Inc.
-
Salarius Pharmaceuticals files prospectus supplement for $810,973 at-the-market offering
At-the-market offering of up to $810,973 of common stock via Ladenburg Thalmann & Co. Inc.
-
Salarius closes Phase 1/2 seclidemstat Ewing sarcoma trial; explores strategic alternatives
Company terminates ongoing Phase 1/2 clinical trial evaluating seclidemstat for Ewing sarcoma to conserve cash.
-
Salarius Pharmaceuticals announces FDA partial clinical hold on seclidemstat trial after grade 4 adverse event
A patient in MDACC's trial of seclidemstat + azacitidine for MDS/CMML experienced a serious unexpected grade 4 adverse event.
-
Salarius reports 43% ORR for seclidemstat combo in MDS/CMML at EHA 2024
Seclidemstat + azacitidine: 43% overall response rate (6/14 evaluable) in higher-risk MDS/CMML patients who failed HMA therapy.
-
Salarius Pharmaceuticals effects 1-for-8 reverse stock split to regain Nasdaq compliance
Reverse split effective 5:00 p.m. ET on June 14, 2024; trading on split-adjusted basis begins June 17.
-
Salarius Pharma gets Nasdaq extension to Sep 3 for bid price compliance; will pursue reverse split if needed
Nasdaq granted Salarius until Sep 3, 2024 to regain $1.00 minimum bid price compliance.
-
Salarius extends cash runway into H1 2025; CEO Arthur transitions to part-time consultant
CEO David Arthur ends full-time employment; becomes part-time consultant effective Feb 20, 2024, at $10,417/month.